Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis.
| Autor: | Lewis JH; Department of Medicine, Division of Gastroenterology-Hepatology, Medstar Georgetown University Hospital, Washington, DC, USA., Korkmaz SY; Department of Medicine, General Internal Medicine, Medstar Georgetown University Hospital, Washington, DC, USA., Rizk CA; Department of Medicine, General Internal Medicine, Medstar Georgetown University Hospital, Washington, DC, USA., Copeland MJ; Department of Medicine, Division of Infectious Diseases, Washington, DC, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Expert opinion on drug safety [Expert Opin Drug Saf] 2024 Sep; Vol. 23 (9), pp. 1093-1107. Date of Electronic Publication: 2024 Sep 04. |
| DOI: | 10.1080/14740338.2024.2399074 |
| Abstrakt: | Introduction: Many of the first line medications for the treatment of active and latent M. tuberculosis are hepatoxic and cause a spectrum of anti-tuberculosis drug induced liver injury (ATLI), including acute liver failure (ALF). Despite advances in recognition of and prevention of ATLI, isoniazid remains one of the leading causes of DILI as well as drug-induced ALF. Areas Covered: A literature search of the incidence, risk factors, current societal guidelines, monitoring, and prophylactic medication usage in ATLI was performed using PubMed and institutional websites. Relevant articles from 1972 to 2024 were included in this review. Expert Opinion: Current societal guidelines regarding ATLI monitoring are mixed, but many recommend liver enzyme testing of high-risk populations. We recommend liver test monitoring for all patients on multi-drug therapy as well as those on isoniazid therapy. Precision medicine practices, such as N-acetyltransferase-2 polymorphism genotyping, are thought to be beneficial in reducing the incidence of ATLI in high-risk populations. However, broader implementation is currently cost prohibitive. Hepatoprotective drugs are not currently recommended, although we do recognize their potential. In patients who develop ATLI but require ongoing anti-TB treatment, strategies to restart the same or less hepatotoxic regimens are currently being followed. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|